Adbry (tralokinumab-ldrm) prior authorization for atopic dermatitis
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline defines prior authorization criteria for initial and reauthorization coverage of Adbry (tralokinumab-ldrm) for members with chronic moderate to severe atopic dermatitis, primarily affecting CareOregon members including Oregon Health Plan considerations.
No material clinical or coverage changes in this revision.
Coverage Criteria for Adbry (tralokinumab-ldrm)
Initial Therapy
Covered when ALL of the following are met:
Approval length: 4 months.
Continuation/Reauthorization
Covered for reauthorization when ALL of the following are met:
Approval length: 12 months.
The Oregon Health Plan (OHP) does not cover treatment with Adbry for atopic dermatitis without functional impairment when the disease does not involve the hand, foot, face, or mucous membranes and when it affects less than 10% of body surface area (BSA). This site- and extent-based exclusion reflects OHP-specific coverage limits and must be applied when assessing medical necessity for members covered under OHP.
Do not approve Adbry when treatment is not medically necessary or appropriate because the dermatitis is driven by contributing factors related to a comorbid condition or when the primary issue is impact on growth, learning, or development rather than intrinsic disease activity. In such situations, address and manage the underlying contributors before considering biologic therapy; approval should be denied if medical necessity for treating the atopic dermatitis itself is not established.
Key Clinical Thresholds and Coding-Related Values
Prior Authorization, Required Therapies, and Documentation
Prior authorization required; initial 4 months, reauth 12 months
Prior authorization is required for Adbry. Initial approvals are granted for 4 months; reauthorizations are granted for 12 months. Initial authorization requires that the member meet the diagnostic and treatment-failure criteria listed in the approval criteria.
- Initial approval length: 4 months
- Reauthorization approval length: 12 months
- Initial authorization requires meeting the listed diagnostic and treatment-failure criteria
Failure of topical steroids, UVB phototherapy, and topical tacrolimus required
Before Adbry can be approved, the member must have failed topical therapies and phototherapy: topical corticosteroids, UVB phototherapy, and topical tacrolimus. Note that topical tacrolimus itself requires a separate prior authorization.
- Failed topical steroids
- Failed UVB phototherapy
- Failed topical tacrolimus (topical tacrolimus requires its own prior authorization)
Failure of two systemic immunosuppressants required
Member must have failed two systemic immunosuppressant agents before approval: choose two from cyclosporine, azathioprine, methotrexate, or mycophenolate.
- Failed two of: cyclosporine, azathioprine, methotrexate, mycophenolate
Document diagnosis, BSA, site involvement, and prior therapy history
Document the diagnosis of chronic, moderate to severe atopic dermatitis with functional impairment and record disease extent and prior therapy history. Specifically, document body surface area, sites involved (hand, foot, face, mucous membranes), and prior therapies tried.
- Document diagnosis of chronic, moderate to severe atopic dermatitis with functional impairment
- Document body surface area (BSA) and sites involved (hand/foot/face/mucous membrane)
- Document prior therapy history and rationale if BSA <10% due to comorbid impact
OHP exclusion: no coverage for limited, non‑functionally impairing disease (<10% BSA or no special-site involvement)
Oregon Health Plan (OHP) will not cover treatment when atopic dermatitis lacks functional impairment and does not involve hand, foot, face, or mucous membranes, or when it affects less than 10% body surface area.
- Atopic dermatitis without functional impairment and without hand/foot/face/mucous membrane involvement is not covered by OHP
- Disease affecting <10% BSA without functional impairment is not covered by OHP
Definitions and Diagnostic Requirements
Background on Adbry (tralokinumab-ldrm)
Adbry (tralokinumab-ldrm) is indicated for chronic moderate to severe atopic dermatitis; this guideline requires documentation that the member’s disease meets the program’s severity criteria before approval. Specifically, approval is contingent on evidence of functional impairment or disease involvement of special sites (hand, foot, face, or mucous membranes) or sufficient body surface area (≥10% BSA). These requirements ensure therapy is reserved for members with clinically meaningful disease burden who are most likely to benefit.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.